INI-678 / Inipharm - LARVOL DELTA

Metabolomic changes in NASH phenotype liver-on-a-chip caused by INI-678, a small molecule HSD17B13 inhibitor, supports a role for HSD17B13 in inflammation and fibrosis (EASL-ILC 2022) - "The decrease in fibrotic markers in NASH LOC with INI- 678 treatment was accompanied by changes in the metabolome. The metabolic changes include stabilization of choline, decreases in bile acids and decreased hexose. The inhibition of HSD17B13 significantly altered metabolism consistent with the hepatoprotective effect and anti-fibrotic effects observed in LOC."

Fibrosis • Gastrointestinal Cancer • Hepatology • Immunology • Inflammation • Liver Cancer • Liver Cirrhosis • Non-alcoholic Steatohepatitis • Oncology • Solid Tumor • PROS1